Related Experiment Video
Updated: Jun 12, 2025

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
The interplay between heart failure and chronic kidney disease
Anuradha Lala1, Adeera Levin2, Kamlesh Khunti3
1Department of Population Health Science, Icahn School of Medicine, New York, New York, USA.
Insights
Chronic kidney disease (CKD) and heart failure (HF) often coexist, worsening each other. Effective management requires recognizing their systemic link and utilizing specific medications and lifestyle changes.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Chronic kidney disease (CKD) and heart failure (HF) are prevalent, independent conditions with a bidirectional relationship.
- CKD and HF frequently coexist, significantly increasing patient morbidity, mortality, hospitalization rates, and impacting quality of life.
- Common risk factors for both CKD and HF include advanced age, diabetes, hypertension, obesity, and smoking.
Purpose of the Study:
- To review the interplay between CKD and HF.
- To emphasize the systemic nature of these co-existing conditions.
- To highlight the role of healthcare professionals in managing patients with both CKD and HF.
Main Methods:
- Literature review discussing the interconnectedness of CKD and HF.
- Analysis of shared risk factors and pathophysiological mechanisms.
- Examination of therapeutic strategies for co-existing CKD and HF.
Main Results:
- Approximately 50% of patients with HF also have CKD.
- The coexistence of CKD and HF leads to a substantially higher risk of adverse outcomes compared to either condition alone.
- Understanding the systemic nature of these diseases is crucial for effective treatment.
Conclusions:
- CKD and HF are systemic conditions with intertwined disease cycles.
- Integrated management strategies are essential for patients with both CKD and HF.
- Key therapeutic agents include renin-angiotensin system inhibitors, SGLT2 inhibitors, finerenone, and GLP-1 receptor agonists, alongside lifestyle modifications.
Abstract:
Chronic kidney disease (CKD) and heart failure (HF) are two globally prevalent, independent, long-term conditions, which often coexist in an individual and display a bidirectional yet interconnected relationship. The presence of CKD often leads to the development of HF and vice versa, which propagates the worsening of each disease, reflecting an intertwined disease cycle. Both HF and CKD share common risk factors, such as increasing age, diabetes, high blood pressure, obesity and smoking. Data show that approximately half of all people with HF also have CKD, which impacts patient burden and quality of life due to a significantly greater risk of hospitalization and death, compared with those that have either CKD or HF. To maximize treatment effectiveness in individuals with both HF and CKD, healthcare professionals should recognize that these two diseases are systemic conditions, representing organ-specific manifestations of similar underlying processes. It is also essential to understand the role of renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitors, the nonsteroidal mineralocorticoid receptor antagonist finerenone, and glucagon-like peptide-1 receptor agonists in managing these conditions. Lifestyle modifications should also be recommended. This review discusses factors contributing to the interplay between HF and CKD and the key role of healthcare professionals in providing appropriate treatment for the co-existing diseases.
Related Concept Videos
Heart Failure Drugs: Diuretics
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Pathophysiology of Heart Failure
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Heart Failure VI: Adjunct Therapies

